Table 1 Significant historical events related to IgE
Year | Name/References | Contribution |
|---|---|---|
1869 | Bakeley [120] | Invented skin tests for allergy diagnosis |
1902 | Richet and Portier [121] | Described the term anaphylaxis |
1906 | Von Pirquet [122] | Used the term “supersensitivity without immunity” to describe symptoms of inhalant allergy and positive skin tests |
1913 | Clowes [123] | Publication of the first successful trial of ragweed subcutaneous immunotherapy |
1919 | Ramirez [124] | Recognized the phenomenon of sensitization, when reporting new horse allergy in a patient who received blood from a horse-allergic donor |
1921 | Prausnitz and Küstner [120] | Described Prausnitz–Küstner (P–K) test, known to sensitize the skin of healthy subjects, through a „transferable sensitization factor“ |
1930 | Coca [125] | Introduced the concept of atopy (hereditary tendency to become allergic) and the term “atopic reagin” as the responsible factor |
1960+ | First epidemiological studies of allergy and cancer risk | |
1964 | Ogilvie [128] | Described reagin-like antibodies in animals immune to helminth parasites |
1965, 1967 | Johansson et al. [129] | A new myeloma protein named IgND found to inhibit P-K activity |
1966 | Ishizaka [130] | Working on an antiserum that could deplete the P-K activity, containing a molecule named γE |
1967 | Wide et al. [131] | RAST (Radio-Allergo Sorbent test) assay development |
1968 | Bennich et al. [1] | Immunoglobulin E discovery announcement |
1971 | Ishizaka [132] | Description of IgE-mediated histamine release |
1971 | Augustin [133] | Published one of the first papers describing IgE levels in cancer and non-cancer patients |
1974 | Ishizaka and Tomioka [134] | First description of IgE-receptors |
1992+ | Mills et al. [135]; Kallen et al. [136]; Vesterinen et al. [137]; Turner et al. [138] | Some first large-scale prospective epidemiological studies of allergy and cancer risk |
1999 | Gould et al. [139] | Reported that IgE antibody-dependent cytotoxicity could be used in suppression of ovarian tumours |
1999 | Milgrom et al. [140] | First randomized placebo-controlled trial using a recombinant humanized monoclonal antibody against IgE (rhuMAb-E25, later named Omalizumab) as treatment in patients with asthma |
2005+ | First epidemiological studies of pre-diagnostic IgE levels and total cancer risk | |
2008+ | Jensen-Jarolim et al. [143]; Penichet and Jensen-Jarolim [120]; Platzer [26] | Defined the new field of AllergoOncology and the potential mechanisms through which IgE has role in tumour surveillance |
2011+ | Calboli et al. [22]; Schlehofer et al. [21]; Schwartzbaum et al. [20] | First epidemiological studies of pre-diagnostic IgE levels and specific cancer risk |
2016 | Simpson et al. [144] | Dupilumab, a fully human monoclonal antibody directed against the interleukin (IL)-4 receptor α subunit, used for treatment in patients with moderate-to-severe atopic dermatitis |
2018 | Karagiannis SN et al. [145] | Initiation of first phase-1 clinical study (NCT02546921) of IgE antibody MOv18 against an ovarian cancer antigen |
2019 | Ferastraoaru and Rosenstreich [34] | First longitudinal study of pre-diagnostic IgE deficiency and cancer risk |
2020 | Spicer JF et al. [80] | Interim data of the first phase-1 clinical study (NCT02546921) of IgE antibody MOv18 against an ovarian cancer antigen presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting |